Ultragenyx Pharmaceutical
Stock Forecast, Prediction & Price Target
Ultragenyx Pharmaceutical Financial Estimates
Ultragenyx Pharmaceutical Revenue Estimates
Ultragenyx Pharmaceutical EBITDA Estimates
Ultragenyx Pharmaceutical Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $351.40M N/A | $363.32M 3.39% | $434.24M 19.51% | Avg: $618.04M Low: $561.20M High: $673.98M avg. 42.32% | Avg: $847.40M Low: $789.15M High: $926.97M avg. 37.11% | Avg: $1.16B Low: $1.08B High: $1.27B avg. 37.74% | Avg: $1.79B Low: $1.66B High: $1.95B avg. 53.36% |
Net Income
% change YoY
| $-454.02M N/A | $-707.42M -55.81% | $-606.63M 14.24% | Avg: $-491.86M Low: $-495.68M High: $-285.35M avg. 18.92% | Avg: $-335.72M Low: $-444.20M High: $-47.06M avg. 31.74% | Avg: $-63.33M Low: $-71.07M High: $-57.67M avg. 81.13% | Avg: $233.40M Low: $212.55M High: $261.89M avg. 468.50% |
EBITDA
% change YoY
| $-381.49M N/A | $-639.41M -67.60% | $-516.45M 19.22% | Avg: $-618.04M Low: $-673.98M High: $-561.20M avg. -19.67% | Avg: $-847.40M Low: $-926.97M High: $-789.15M avg. -37.11% | Avg: $-1.16B Low: $-1.27B High: $-1.08B avg. -37.74% | Avg: $-1.79B Low: $-1.95B High: $-1.66B avg. -53.36% |
EPS
% change YoY
| -$6.7 N/A | -$10.12 -51.04% | -$8.25 18.47% | Avg: -$5.4 Low: -$6.74 High: -$3.88 avg. 34.50% | Avg: -$3.63 Low: -$6.04 High: -$0.64 avg. 32.88% | Avg: -$0.86 Low: -$0.97 High: -$0.78 avg. 76.25% | Avg: $3.17 Low: $2.89 High: $3.56 avg. 468.50% |
Operating Expenses
% change YoY
| $717.13M N/A | $983.92M 37.20% | $958.24M -2.60% | Avg: $536.12M Low: $486.82M High: $584.65M avg. -44.05% | Avg: $735.09M Low: $684.56M High: $804.11M avg. 37.11% | Avg: $1.01B Low: $942.93M High: $1.10B avg. 37.74% | Avg: $1.55B Low: $1.44B High: $1.69B avg. 53.36% |
FAQ
What is Ultragenyx Pharmaceutical stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 150.07% in 2025-2028.
We have gathered data from 16 analysts. Their low estimate is -495.68M, average is -491.86M and high is -285.35M.
What is Ultragenyx Pharmaceutical stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 42.63% in 2025-2028.
We have gathered data from 15 analysts. Their low revenue estimate is $561.20M, average is $618.04M and high is $673.98M.
What is Ultragenyx Pharmaceutical stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 153.03% in 2025-2028.
We have gathered data from 16 analysts. Their low earnings per share estimate is -$6.74, average is -$5.4 and high is $-3.88.
What is the best performing analyst?
In the last twelve months analysts have been covering Ultragenyx Pharmaceutical stock. The most successful analyst is Ed Arce.